TEACH, NCT04281420: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma |
|
|
| Terminated | 1 | 20 | RoW | ATG-019, KPT-9274, ATG-019 + Niacin ER | Antengene Therapeutics Limited | Solid Tumor, Non-Hodgkin's Lymphoma | 10/23 | 10/23 | | |
NCT04914845: KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 40 | US | KPT-9274 | University of Colorado, Denver, Karyopharm Therapeutics Inc | Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | 02/26 | 02/27 | | |
